BioCentury
ARTICLE | Clinical News

Prolia denosumab: Phase III data

September 5, 2016 7:00 AM UTC

Top-line data from the double-blind, double-dummy, international Phase III GIOP trial in 795 patients receiving glucocorticoid treatment showed that 60 mg subcutaneous Prolia every 6 months met the pr...